Argo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218

P SHANGHAI and NEW YORK, April 28, 2026 /PRNewswire/ — Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies,…
posteditor
posteditor
Articles: 27509

Other News